A5029411467- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Cancer-related molecular mechanisms research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Cells and Metastasis
- DNA Repair Mechanisms
- Ferroptosis and cancer prognosis
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Cancer Research and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Peptidase Inhibition and Analysis
- Brain Metastases and Treatment
- Epigenetics and DNA Methylation
- Gastric Cancer Management and Outcomes
- Immunotherapy and Immune Responses
- Hepatocellular Carcinoma Treatment and Prognosis
- Cytokine Signaling Pathways and Interactions
- Radiomics and Machine Learning in Medical Imaging
Tongji University
2016-2025
Shanghai Pulmonary Hospital
2016-2025
Shanghai East Hospital
2024-2025
Bengbu Medical College
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2022
The First Affiliated Hospital, Sun Yat-sen University
2014-2019
Zhongshan Hospital
2014-2019
Fudan University
2014-2019
Sun Yat-sen University
2014-2019
Soochow University
2019
Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched and blood samples from the FASTACT-2 study.Patients were randomized receive six cycles of gemcitabine/platinum plus sequential erlotinib or placebo. was performed using cobas tissue test (in development). Blood at baseline, cycle 3, progression assessed for detection rate, sensitivity, specificity; concordance with (n = 238), correlation...
<h3>Importance</h3> Metastatic non–small cell lung cancer (mNSCLC) with<i>EGFR</i>exon 20 insertion (<i>EGFR</i>ex20ins) mutations is associated with a poor prognosis. Mobocertinib an oral tyrosine kinase inhibitor designed to selectively target<i>EGFR</i>ex20ins mutations. <h3>Objective</h3> To evaluate treatment outcomes and safety of mobocertinib in patients previously treated<i>EGFR</i>ex20ins-positive mNSCLC. <h3>Design, Setting, Participants</h3> This 3-part, open-label, phase 1/2...
BackgroundEffective targeted therapy for non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This study investigated the antitumor effect of irreversible pan-HER tyrosine kinase inhibitor, pyrotinib.Patients and methodsUsing patient-derived organoids xenografts established from HER2-A775_G776YVMA-inserted advanced adenocarcinoma patient sample, we activity pyrotinib. Preliminary safety efficacy pyrotinib in 15...
IMpower010 (NCT02486718) demonstrated significantly improved disease-free survival (DFS) with adjuvant atezolizumab versus best supportive care (BSC) following platinum-based chemotherapy in the programmed death-ligand 1 (PD-L1)-positive and all stage II-IIIA non-small-cell lung cancer (NSCLC) populations, at DFS interim analysis. Results of first analysis overall (OS) are reported here.The design, participants, primary-endpoint outcomes have been for this phase III, open-label, : randomised...
8500 Background: Adjuvant platinum-based chemotherapy (chemo) provides only a modest 5-year survival benefit in fully resected, high-risk early-stage NSCLC. We report the primary disease-free (DFS) results from pre-planned interim analysis of IMpower010, randomized phase 3 open-label trial adjuvant atezolizumab (atezo; anti–PD-L1) vs best supportive care (BSC) after chemo patients (pts) with resected Methods: Eligible pts had completely (4-12 weeks prior to enrollment) Stage IB (≥4 cm)-IIIA...
// Ningning Cheng 1,* , Weijing Cai Shengxiang Ren 1 Xuefei Li 2 Qi Wang Hui Pan Mingchuan Zhao Jiayu Yishi Zhang Chao Xiaoxia Chen Ke Fei 3 Caicun Zhou and Fred R. Hirsch 4 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, University School Cancer Institute, Shanghai, P. China Lung Immunology, Thoracic Surgery, Pathology, Colorado Center, Aurora, Colorado, USA * These authors have contributed equally to this work Correspondence to: Zhou, email: Keywords : UCA1,...
ARID1A alterations would compromise mismatch repair pathway and increase the number of tumor-infiltrating lymphocytes PD-L1 expression in some cancers, which cooperate with immune checkpoint inhibitors (ICIs) treatment. However, a comprehensive analysis alteration frequency its predictive value for ICI treatment outcome cancers has not yet been investigated. Hence, we performed this pan-cancer to evaluate prevalence across >40,000 cases multiple cancer types. We found high (6.2%) ARID1A,...
This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC. Patients who failed from first-line EGFR-TKIs did not harbor T790M mutation were enrolled. Toripalimab carboplatin pemetrexed administrated every three weeks for up six cycles, followed by maintenance pemetrexed. The primary endpoint was objective-response rate (ORR). Integrated biomarker...
Abstract Background Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall (OS) compared to alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) the phase III trial (CameL-sq), which has become an option of standard-of-cares for Chinese patients with LUSC. However, predictive biomarkers remain unknown. Methods Tumor tissue samples at baseline, peripheral blood baseline (pretreatment) after two cycles (on-treatment) were...
Lymph node (LN) dissection is a common procedure for non-small cell lung cancer (NSCLC) to ascertain disease severity and treatment options. However, murine studies have indicated that excising tumor-draining LNs diminished immunotherapy effectiveness, though its applicability clinical patients remains uncertain. Hence, the authors aim illustrate immunological implications of LN by analyzing impact dissected (DLN) count on efficacy, propose novel 'immunotherapy-driven' strategy.
We have previously identified a panel of autoantibodies (AABs), including p53, GAGE7, PGP9.5, CAGE, MAGEA1, SOX2 and GBU4-5, that was helpful in the early diagnosis lung cancer. This large-scale, multicenter study undertaken to validate clinical value this 7-AABs for detection cancer Chinese population. Two independent sets plasma samples from 2308 participants were available assay AABs (training set = 300; validation 2008). The concentrations quantitated by enzyme-linked immunosorbent...